Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF)
OTCMKTS
· Delayed Price · Currency is USD
1.570
+0.020 (1.29%)
At close: Jan 15, 2025
SHPMF Revenue
Shanghai Pharmaceuticals Holding had revenue of 70.22B CNY in the quarter ending September 30, 2024, with 8.16% growth. This brings the company's revenue in the last twelve months to 272.42B, up 6.88% year-over-year. In the year 2023, Shanghai Pharmaceuticals Holding had annual revenue of 260.30B with 12.21% growth.
Revenue (ttm)
272.42B CNY
Revenue Growth
+6.88%
P/S Ratio
n/a
Revenue / Employee
5.66M CNY
Employees
48,164
Market Cap
8.90B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 260.30B | 28.31B | 12.21% |
| Dec 31, 2022 | 231.98B | 16.16B | 7.49% |
| Dec 31, 2021 | 215.82B | 23.92B | 12.46% |
| Dec 31, 2020 | 191.91B | 5.34B | 2.86% |
| Dec 31, 2019 | 186.57B | 27.48B | 17.27% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| Veradigm | 1.53B |
| SS Innovations International | 16.04M |
| Elite Pharmaceuticals | 71.17M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| BioStem Technologies | 210.49M |
| Silence Therapeutics | 21.77M |
Shanghai Pharmaceuticals Holding News
- 18 days ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
- 19 days ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha